Videos

Dr. McCloskey discusses the general principles and practices for monitoring and mitigating adverse events, particularly capillary leak syndrome (CLS), in BPDCN patients treated with systemic agents like tagraxofusp.

Dr. McCloskey examines the potential of anti-CD123 CAR T-cell therapy for BPDCN, including the main challenges and limitations of this therapeutic approach.

Dr. McCloskey discusses the recent clinical trial results, such as the CADENZA trial, on the efficacy and safety of tagraxofusp in BPDCN patients.

Dr. McCloskey explores the mechanism of action and potential efficacy of tagraxofusp in the treatment of BPDCN.

Dr. McCloskey discusses the appropriateness of the initial therapy (tagraxofusp) based on NCCN guidelines, as well as the benefits and limitations of current treatment regimens for BPDCN.

Dr. McCloskey provides a brief overview of blastic plasmacytoid dendritic cell neoplasm (BPDCN), including the clinical hallmarks of the disease and the challenges in recognizing and diagnosing this rare condition.

Lova Sun, MD, discusses the importance of identifying genetic alterations in thyroid cancer, including RET and NTRK alterations.

Neal Shore, MD, FACS, concludes by addressing the remaining unmet needs in the management of non-metastatic castration-resistant prostate cancer.

Neal Shore, MD, FACS, explains how he integrates findings from the ARAMIS trial to inform patient treatment decisions while prioritizing patient values and personal preferences.

Neal Shore, MD, FACS, outlines his treatment approach, which favors single agents over combination therapies, and incorporates bone-health drugs, vitamins, nutrition guidance, and exercise recommendations to support patients. While PSA remains a valuable biomarker in prostate cancer, he notes that ctDNA and aspects of MRD are gaining importance, although not yet widely adopted.

Saad Z. Usmani, MD, MBA, FACP, FASCO, delves into the development of new treatments for patients with multiple myeloma.

David L. Bartlett, MD, discusses the benefits of genomic testing for patients with cancer and how the approach to genomic testing has changed over the years.

Dr. Motzer discusses the future of nccRCC management and emerging data or unmet needs he is following.

Discussing the appropriateness of the initial therapy based on the NCCN guidelines for the given patient case.

Neal Shore, MD, FACS provides an analysis of the ARAMIS, SPARTAN, and PROSPER trials, which demonstrate improved survival in high-risk non-metastatic castration-resistant prostate cancer through early intervention, highlighting the potential for preventing disease progression based on the data from these pivotal studies.

Exploring the main treatment goals and current first-line and second-line treatment options for patients with chronic GvHD.

Neal Shore, MD, FACS, reviews the case of a 75-year-old man with non-metastatic castration-resistant prostate cancer, seeks to evaluate the timeline of rising PSA to determine the aggressiveness of the disease, and considers the patient an excellent candidate for antigen receptor pathway inhibition.

Lori J. Wirth, MD, discusses the outcomes of treatment with larotrectinib for patients with NTRK fusion–positive advanced thyroid cancer.

Amer Zeidan, MBBS, explains how the approval of imetelstat may impact patients with myelodysplastic syndromes.

A medical oncologist provides a comprehensive overview of HER2-targeting agents in breast cancer and considerations to factor into treatment decisions.

Amer Zeidan, MBBS, discusses the recent expansion of the indication for luspatercept-amt to the frontline setting to treat anemia in patients with lower-risk myelodysplastic syndromes.

Amer Zeidan, MBBS, discusses the unmet needs that exist for myelodysplastic syndromes and how imetelstat may help fill these needs.

Following a discussion centered on the EV-302 study, Thomas Powles, MBBS, MRCP, MD, and the Oncology Brothers discuss the role of circulating tumor DNA in urothelial cancer.

A comprehensive discussion on treatment-related adverse events seen in patients receiving enfortumab vedotin and pembrolizumab.

The Oncology Brothers are joined by Thomas Powles, MBBS, MRCP, MD, to discuss the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.

Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers to discuss the study design and results of the EV-302 trial investigating enfortumab vedotin plus pembrolizumab in untreated advanced urothelial carcinoma.

Amer Zeidan, MBBS, discusses how imetelstat compares with other treatments for patients with low-risk myelodysplastic syndromes with anemia who are transfusion-dependent and ineligible for erythropoiesis stimulating agents.

Daniel H. Ahn, DO, discusses how regorafenib continues to benefit patients with advanced colorectal cancer as researchers look to modify treatment strategies with the therapy.

Dr. Plimack shares her insights on some unmeet needs and challenges when treating non-clear cell renal cell carcinoma.

Lova Sun, MD, discusses genetic alterations in thyroid cancer, including RET and NTRK alterations, and how these can affect treatment options.